Loading
companiesCompany
German CLL Study Group
The German CLL Study Group, founded in 1996 at the University of Cologne, runs the numbered CLL trials that set first-line treatment of chronic lymphocytic leukaemia, including CLL12, CLL13 (GAIA) and CLL14 in OnCo.
Also called: Deutsche CLL StudiengruppeDCLLSGGCLLSG
Overview
The Deutsche CLL Studiengruppe (DCLLSG, German CLL Study Group) was founded in 1996 to improve the diagnosis and treatment of chronic lymphocytic leukaemia through controlled prospective trials, and describes itself as a research organisation of the University of Cologne specialising in CLL (dcllsg.de). ClinicalTrials.gov names it lead sponsor (OTHER class) of CLL12 (NCT02863718, phase 3, ibrutinib against placebo in early-stage CLL, with Janssen-Cilag as collaborator) and of CLL13 / GAIA (NCT02950051, phase 3, venetoclax combinations against chemoimmunotherapy in fit treatment-naive CLL, with Janssen-Cilag, Roche, AbbVie, HOVON, the Nordic CLL Study Group and others as collaborators); on CLL14 (NCT02242942, venetoclax and obinutuzumab in unfit CLL) the registry lead is Hoffmann-La Roche and the group is a collaborator, as the OnCo record's sponsor line says. It has no products of its own.
Headquarters
Cologne, DE
Website
Founded
1996
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-10-01.
Matched to Deutsche CLL Studiengruppe (DCLLSG), including child institutions. 5 works · 37 citations · 80% open access · 0% clinical trials · 0% reviews.
Oncology works per year
02022
12023
32024
12025
02026
Most works
- Udo Holtick3 works
- Nadine Kutsch3 works
- Giuliano Filippini Velázquez2 works
- Gloria Iacoboni2 works
- Rebecca Wurm‐Kuczera2 works
- Peter Borchmann2 works
- Bjoern Chapuy2 works
- Julia Katharina Scholz2 works
- Özlem Türeci1 works
- Daniel Heudobler1 works
Most cited
| Work | Journal | Year | Citations |
|---|---|---|---|
| Beyond maximum grade: tolerability of immunotherapies, cellular therapies, and targeted agents in haematological malignancies 10.1016/s2352-3026(25)00051-1 · open access | The Lancet Haematology | 2025 | 19 |
| CLDN6 CAR-T cell therapy of relapsed/refractory solid tumors ± a CLDN6-encoding mRNA vaccine: Dose escalation data from the BNT211-01 phase 1 trial using an automated product. conference abstract · 10.1200/jco.2023.41.16_suppl.2518 | Journal of Clinical Oncology | 2023 | 8 |
| Time of CAR-T Failure Is a Strong Predictor of Outcome for Bispecific Antibody Therapy in Relapsed/Refractory Large B-Cell Lymphoma | Blood | 2024 | 6 |
| Inflammation-Based Scores Predict Survival after CD3xCD20 Bispecific T Cell Engagers in R/R LBCL | Blood | 2024 | 2 |
| Long‐term remission in a patient with relapsed Richter's transformation treated with CD19‐directed chimeric antigen‐receptor T‐cells after allogeneic stem cell transplantation 10.1111/ejh.14182 · open access | European Journal Of Haematology | 2024 | 2 |
Similar pages
- CompanyNordic Lymphoma Group
Shares Chronic lymphocytic leukaemia and the tag cooperative-group.
- CompanyGIMEMA
Shares Chronic lymphocytic leukaemia and the tag cooperative-group.
- CompanyHOVON
Shares Chronic lymphocytic leukaemia and the tag cooperative-group.
- Key paperCLL12: ibrutinib in early-stage chronic lymphocytic leukaemia, a randomised placebo-controlled phase 3 trial
Shares CLL12, Chronic lymphocytic leukaemia, first treatment, Chronic lymphocytic leukaemia.
- PairingVenetoclax + obinutuzumab (12 months)
Shares CLL14, CLL13 / GAIA, Chronic lymphocytic leukaemia, first treatment, Chronic lymphocytic leukaemia.
- PersonMichael Hallek
Shares CLL14, CLL13 / GAIA, Chronic lymphocytic leukaemia.
- TermIGHV mutational status
Shares CLL13 / GAIA, Chronic lymphocytic leukaemia, first treatment, Chronic lymphocytic leukaemia.
- TrialSurovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin He
Shares Chronic lymphocytic leukaemia, first treatment, Chronic lymphocytic leukaemia.